期刊文献+

简体中文版老年男性症状量表的信效度检验 被引量:4

Reliability and validity of the simplified Chinese version of the Aging Males′Symptoms Scale
下载PDF
导出
摘要 目的检验简体中文版老年男性症状量表(AMS)在前列腺癌内分泌治疗患者中的适用性。方法对繁体中文版AMS进行文化调适,形成简体中文版AMS,邀请10名专家进行内容效度评定,并对221例前列腺癌内分泌治疗患者进行问卷调查,检验简体中文版AMS的信度和效度。结果简体中文版AMS的内容效度指数为0.95;量表含17个条目,探索性因子分析提取3个公因子,累积方差贡献率为60.801%;总量表的Cronbach′sα系数为0.871,折半信度为0.748。结论简体中文版AMS量表具有较好的信效度,可作为前列腺癌内分泌治疗患者雄激素缺乏相关不良反应的症状评估工具。 Objective To test the applicability of the simplified Chinese version of the Aging Males′Symptoms Scale(AMS)in prostate cancer patients receiving hormonal therapy.Methods The traditional Chinese version of AMS was culturally adapted to form the simplified Chinese version,then 10 experts were invited to evaluate the content validity.After that,221 prostate cancer patients receiving hormonal therapy were investigated to test the reliability and validity of the simplified Chinese version of AMS.Results The content validity index for the scale was 0.95.The scale contained 17 items,and 3 factors were identified by exploratory factor analysis,accounting for 60.801%of the total variance.The Cronbach′s alpha coefficient of the total scale was 0.871 and the split-half reliability was 0.748.Conclusion The simplified Chinese version of AMS has good reliability and validity,and can be used as a symptom assessment tool for androgen deficiency related adverse reactions in prostate cancer patients receiving hormonal therapy.
作者 杨锐 陆箴琦 顾晓锋 Yang Rui;Lu Zhenqi;Gu Xiaofeng(Nursing Department of Cancer Hospital,Fudan University,Shanghai 200032,China)
出处 《护理学杂志》 CSCD 北大核心 2020年第5期31-34,共4页 Journal of Nursing Science
基金 复旦大学复星护理科研基金(FNF201818)。
关键词 前列腺癌 内分泌治疗 不良反应 雄激素 老年男性症状量表 信度 效度 prostate cancer hormonal therapy adverse reactions androgen the Aging Males′Symptoms scale reliability validity
  • 相关文献

参考文献4

二级参考文献49

  • 1侯树坤.应重视雄激素撤除治疗的不良事件[J].中华泌尿外科杂志,2005,26(6):365-366. 被引量:14
  • 2Siegel R L, Miller K D, Jemal A. Cancer statistics, 2016 [J]. CACancer J Clin, 2016, 66(1): 7-30.
  • 3Chen W, Zheng R, Baade P D, et al. Cancer statistics in China,2015[J], CA Cancer J Clin, 2016, 66(2):115-132.
  • 4Chopra S, Rashid P. Management of castration-resistant (ad-vanced) prostate cancer (CRPC): rationale, progress and futuredirections[J].Aust Fam Physician, 2015, 44(5): 302-305.
  • 5Molina A, Belldegrun A. Novel therapeutic strategies for castrationresistant prostate cancer: inhibition of persistent androgen pro-duction and androgen receptor mediated signalingfj]. J Urol, 2011,185(3):787-794.
  • 6Scher H I, Fizazi K, Saad F, et al. Increased survival with enzalu-tamide in prostate cancer after chemotherapy[J]. N Eng丨 J Med,2012,367(13):1187-1197.
  • 7Pienta K J. Preclinical mechanisms of action of docetaxel and do-cetaxel combinations in prostate cancer[J], Semin Oncol, 2001,28(4Suppl 15):3-7.
  • 8Paller C J, Antonarakis E S. Cabazitaxei: a novel second-linetreatment for metastatic castration-resistant prostate cancer [J],Drug Des Devel Ther, 2011(5):117-124.
  • 9巳ertholdD R, Pond G R, Soban F, et at. Docetaxel plus prednisoneor mitoxantrone plus prednisone for advanced prostate cancer:updated survival in the TAX 327 study[J]. J Clin Oncol, 2008, 26(2):242-245.
  • 10Oudard S, Banu E, Beuzeboc P, et af. Multicenter randomizedphase It study of two schedules of docetaxel, estramustine, andprednisone versus mitoxantrone plus prednisone in patients withmetastatic hormone-refractory prostate cancer[J]. J Clin Oncol,2005, 23(15):3343-3351.

共引文献815

同被引文献67

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部